Inventor · disambiguated record
Christopher L. Lynch
Also filed as: LYNCH CHRISTOPHER · LYNCH CHRISTOPHER L
26 granted patents·5 pending applications·1,286 citations·filing 1998–2014
97Inventor score
Top patents by PatentIndex Score
31 records- 0198US7973161B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jul 5, 2011·70 cites·5 claims
- 0298US7767684B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Aug 3, 2010·107 cites·7 claims
- 0398US7642260B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Jan 5, 2010·82 cites·2 claims
- 0498US7390799B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jun 24, 2008·331 cites·12 claims
- 0597US8686136B2Apoptosis promotersABBVIE INC·Filed 2012·Granted Apr 1, 2014·20 cites·2 claims
- 0697US8354404B2Apoptosis promotersABBOTT LAB·Filed 2011·Granted Jan 15, 2013·39 cites·8 claims
- 0797US8173811B2Apoptosis promotersBRUNCKO MILAN·Filed 2010·Granted May 8, 2012·50 cites·4 claims
- 0897US7709467B2Apoptosis promotersABBOTT LAB·Filed 2008·Granted May 4, 2010·50 cites·10 claims
- 0996US8614318B2Apoptosis promotersBRUNCKO MILAN·Filed 2006·Granted Dec 24, 2013·37 cites·2 claims
- 1096US8084607B2Apoptosis promotersBRUNCKO MILAN·Filed 2009·Granted Dec 27, 2011·43 cites·5 claims
- 1196US6166037APyrrolidine and piperidine modulators of chemokine receptor activityMERCK & CO INC·Filed 1998·Granted Dec 26, 2000·171 cites·25 claims
- 1295US9045444B2Apoptosis promotersABBVIE INC·Filed 2014·Granted Jun 2, 2015·11 cites·3 claims
- 1394US7872017B2Fused bicycloheterocycle substituted azabicyclic alkane derivativesABBOTT LAB·Filed 2007·Granted Jan 18, 2011·31 cites·14 claims
- 1493US7906505B2Apoptosis promotersABBOTT LAB·Filed 2010·Granted Mar 15, 2011·18 cites·4 claims
- 1590US6248755B1Pyrrolidine modulators of chemokine receptor activityMERCK & CO INC·Filed 2000·Granted Jun 19, 2001·52 cites·39 claims
- 1689US7741364B2Pyrrole derivatives and their methods of useABBOTT LAB·Filed 2007·Granted Jun 22, 2010·23 cites·7 claims
- 1788US6399619B1Pyrrolidine modulators of chemokine receptor activityMERCK & CO INC·Filed 2000·Granted Jun 4, 2002·23 cites·28 claims
- 1887US7777076B2Macrocyclic inhibitors of BCL proteinsABBOTT LAB·Filed 2006·Granted Aug 17, 2010·6 cites·4 claims
- 1987US7309721B2Aminoalkylphosphonates and related compounds as Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Dec 18, 2007·37 cites·15 claims
- 2086US7479504B2Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Jan 20, 2009·28 cites·5 claims
- 2182US7199142B21-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Apr 3, 2007·21 cites·12 claims
- 2280US6265434B1Pyrrolidine modulators of chemokine receptor activityMERCK & CO INC·Filed 2000·Granted Jul 24, 2001·17 cites·36 claims
- 2379US6498161B1Pyrrolidine modulators of chemokine receptor activityMERCK & CO INC·Filed 2000·Granted Dec 24, 2002·12 cites·43 claims
- 2472US8609713B2Pyrrole derivatives and their methods of useFAGHIH RAMIN·Filed 2010·Granted Dec 17, 2013·3 cites·13 claims
- 2572US8470813B2Thiazoline and oxazoline derivatives and their methods of useFAGHIH RAMIN·Filed 2010·Granted Jun 25, 2013·3 cites·9 claims
- 2660US7125887B2Pyrrolidine modulators of CCR5 chemokine receptor activityMERCK & CO INC·Filed 2001·Granted Oct 24, 2006·1 cites·27 claims
- 2754US2005159427A1N-acylsulfonamide apoptosis promotersFiled 2004·Application pending·0 cites
- 2845US2010305089A1Fused Bicycloheterocycle Substituted Azabicyclic Alkane DerivativesABBOTT LAB·Filed 2010·Application pending·0 cites
- 2943US2007043014A13,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonistsMERCK & CO INC·Filed 2004·Application pending·0 cites
- 3038US2002094989A1Pyrrolidine modulators of CCR5 chemokine receptor activityFiled 2001·Application pending·0 cites
- 3138US2006252741A13-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonistsCOLANDREA VINCENT J·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →